论文部分内容阅读
通过DNA重组技术生产的大量细胞因子为抗肿瘤治疗的进展提供了良好的机会.肿瘤坏死因子(TNF)的临床研究正是其中的一大方面.那些在临床试验中惯用化疗的人必须准备好改变以往的方法来迎接新问题.当然,在将细胞因子应用到临床抗肿瘤治疗的同时,仍要应用化疗药物发展过程中的一些经验,只有传统与创新方法结合用于临床才能使新制剂的研制获得成功.
The large number of cytokines produced by DNA recombination technology provides a good opportunity for the development of anti-tumor therapy. The clinical research of tumor necrosis factor (TNF) is one of the major aspects. Those who have used chemotherapy in clinical trials must be prepared. Change the previous methods to meet new problems. Of course, while applying cytokines to clinical anti-tumor therapy, some experience in the development of chemotherapeutic drugs is still to be applied. Only the combination of traditional and innovative methods can be used clinically to make new preparations. Development is successful.